These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34413054)

  • 1. Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma.
    Sterling J; Hua P; Dunaief JL; Cui QN; VanderBeek BL
    Br J Ophthalmol; 2023 Feb; 107(2):215-220. PubMed ID: 34413054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical and systemic GLP-1R agonist administration both rescue retinal ganglion cells in hypertensive glaucoma.
    Lawrence ECN; Guo M; Schwartz TD; Wu J; Lu J; Nikonov S; Sterling JK; Cui QN
    Front Cell Neurosci; 2023; 17():1156829. PubMed ID: 37362000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists Exposure and Intraocular Pressure Change.
    Hallaj S; Halfpenny W; Chuter BG; Weinreb RN; Baxter SL; Cui QN
    medRxiv; 2024 May; ():. PubMed ID: 38765972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescription of glucagon-like peptide 1 agonists and risk of subsequent open-angle glaucoma in individuals with type 2 diabetes mellitus.
    Chuang CC; Wang K; Chang CK; Lee CY; Huang JY; Wu HH; Yang PJ; Yang SF
    Int J Med Sci; 2024; 21(3):540-546. PubMed ID: 38250602
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y
    Yuan Y; Yan Z; Lao Q; Jiang N; Wu S; Lu Q; Han J; Zhao S
    Eur J Med Chem; 2023 Feb; 247():115036. PubMed ID: 36571995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism.
    Al Batran R; Almutairi M; Ussher JR
    Peptides; 2018 Feb; 100():94-100. PubMed ID: 29412838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.
    Chen JJ; Wu CY; Jenq CC; Lee TH; Tsai CY; Tu HT; Huang YT; Yen CL; Yen TH; Chen YC; Tian YC; Yang CW; Yang HY
    JAMA Netw Open; 2022 Mar; 5(3):e221169. PubMed ID: 35254430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys.
    Elvert R; Bossart M; Herling AW; Weiss T; Zhang B; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Keil S; Lorenz M; Lorenz K; Riz M; Hennerici W; Larsen PJ
    Endocrinology; 2018 Aug; 159(8):3105-3119. PubMed ID: 29992313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis.
    Xue H; Xing HJ; Wang B; Fu C; Zhang YS; Qiao X; Guo C; Zhang XL; Hu B; Zhao X; Deng LJ; Zhu XC; Zhang Y; Liu YF
    Drug Des Devel Ther; 2023; 17():1417-1432. PubMed ID: 37197367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide-1 receptor action in the vasculature.
    Almutairi M; Al Batran R; Ussher JR
    Peptides; 2019 Jan; 111():26-32. PubMed ID: 30227157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
    Guo XH
    Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Glucagon-Like Peptide-1 Receptor Agonists Exposure and Intraocular Pressure Change: GLP-1 Receptor Agonists and Intraocular Pressure Change.
    Hallaj S; Halfpenny W; Chuter BG; Weinreb RN; Baxter SL; Cui QN
    Am J Ophthalmol; 2025 Jan; 269():255-265. PubMed ID: 39237049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes.
    Hernández C; Bogdanov P; Corraliza L; García-Ramírez M; Solà-Adell C; Arranz JA; Arroba AI; Valverde AM; Simó R
    Diabetes; 2016 Jan; 65(1):172-87. PubMed ID: 26384381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do glucagon-like peptide-1 receptor (GLP-1R) agonists have potential as adjuncts in the treatment of type 1 diabetes?
    Doggrell SA
    Expert Opin Pharmacother; 2018 Oct; 19(15):1655-1661. PubMed ID: 30234389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential benefits of glucagon-like peptide-1 receptor agonists for diabetic retinopathy.
    Pang B; Zhou H; Kuang H
    Peptides; 2018 Feb; 100():123-126. PubMed ID: 28807775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
    Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
    BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are GLP-1R agonists the long-sought-after panacea for obesity?
    Dowsett GKC; Yeo GSH
    Trends Mol Med; 2023 Oct; 29(10):777-779. PubMed ID: 37460364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The alpha-7 nicotinic acetylcholine receptor agonist GTS-21 engages the glucagon-like peptide-1 incretin hormone axis to lower levels of blood glucose in db/db mice.
    Meng Q; Chepurny OG; Leech CA; Pruekprasert N; Molnar ME; Collier JJ; Cooney RN; Holz GG
    Diabetes Obes Metab; 2022 Jul; 24(7):1255-1266. PubMed ID: 35293666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease.
    Foer D; Amin T; Nagai J; Tani Y; Feng C; Liu T; Newcomb DC; Lai J; Hayashi H; Snyder WE; McGill A; Lin A; Laidlaw TM; Niswender KD; Boyce JA; Cahill KN
    J Immunol; 2023 Dec; 211(12):1806-1813. PubMed ID: 37870292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.